Performa Ltd (US)’s VistaGen Therapeutics VTGN Stock Holding History

Performa Ltd (US)’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.24K	Sell	5,500 -2,000	-27%	-$1.21K	﹤0.01%	49
2026 Q1	$4.29K	Buy	7,500 +6,500	+650%	+$3.95K	﹤0.01%	40
2025 Q4	$662	Hold	1,000	–	–	﹤0.01%	50
2025 Q3	$3.55K	Hold	1,000	–	–	﹤0.01%	43
2025 Q2	$2K	Hold	1,000	–	–	﹤0.01%	49
2025 Q1	$2.5K	Hold	1,000	–	–	﹤0.01%	50
2024 Q4	$2.95K	Buy	+1,000	New	+$2.81K	﹤0.01%	45
2023 Q3	–	Sell	-4,900	Closed	-$9.16K	–	78
2023 Q2	$9.16K	Buy	4,900 +1,900	+63%	+$6.66K	﹤0.01%	41
2023 Q1	$11.2K	Buy	3,000 +667	+29%	+$3.5K	0.01%	36
2022 Q4	$7.21K	Buy	2,333 +333	+17%	+$1.25K	﹤0.01%	44
2022 Q3	$9K	Buy	2,000 +971	+94%	+$9.62K	0.01%	40
2022 Q2	$27K	Buy	1,029 +279	+37%	+$9.85K	0.02%	19
2022 Q1	$28K	Buy	750 +417	+125%	+$18.2K	0.02%	19
2021 Q4	$20K	Buy	333 +266	+397%	+$17.3K	0.01%	25
2021 Q3	$5K	Buy	67 +10	+18%	+$869	﹤0.01%	34
2021 Q2	$5K	Buy	+57	New	+$4.22K	﹤0.01%	20

Other funds holding VTGN

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

CWS

Confluence Wealth Services Mcmurray, Pennsylvania $3.5B AUM 22.08% 1-Year Est. Return

Performa Ltd (US)'s VTGN Position: Q2 2026 in Review

Performa Ltd (US) reduced its VistaGen Therapeutics (VTGN) stake by 27% in Q2 2026, selling an estimated $1.21K and leaving 5,500 shares worth $1.24K. The position accounts for ﹤0.01% of the portfolio, ranked #49.

Performa Ltd (US) first reported a position in VTGN in Q2 2021 and has held it in 16 quarters since. The position peaked at $28K in Q1 2022. 26 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

Performa Ltd (US) held 5,500 shares of VistaGen Therapeutics worth $1.24K as of Q2 2026.
Performa Ltd (US) sold 2,000 VistaGen Therapeutics shares in Q2 2026, an estimated $1.21K.
VistaGen Therapeutics made up ﹤0.01% of Performa Ltd (US)'s portfolio in Q2 2026, its #49 holding.
Performa Ltd (US) first reported a position in VistaGen Therapeutics in Q2 2021 and has held it in 16 quarters since.
Performa Ltd (US)'s VistaGen Therapeutics position peaked at $28K in Q1 2022.
26 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Performa Ltd (US)'s 13F filing for Q2 2026, filed 3 Aug 2026.